Clinical trial
Study of REGN 2810 Compared to Platinum-Based Chemotherapies in Participants…
NCT03088540 · Regeneron Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT03088540 |
|---|---|
| Title | Study of REGN 2810 Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) |
| Official title | A Global, Randomised, Phase 3, Open-label Study of REGN2810 (ANTI-PD 1 Antibody) Versus Platinum Based Chemotherapy in First Line Treatment of Patients With Advanced or Metastatic PD L1+Non-small Cell Lung Cancer |
| Lead sponsor | Regeneron Pharmaceuticals, Industry |
| Collaborators | Sanofi Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Carcinoma，Non-Small-Cell Lung, Lung Carcinomas, Non-Small-Cell, Non-small-cell Lung Carcinoma, Nonsmall Cell Lung Cancer |
| Intervention type | Drug |
| Interventions | Pemetrexed, Paclitaxel, Gemcitabine, Cisplatin, Carboplatin, cemiplimab |
| Enrollment | 712 |
| Start date | May 29, 2017 |
| Primary completion | Apr 18, 2025 |
| Completion | Apr 18, 2025 |
| First posted | Mar 23, 2017 |
| Last update posted | May 4, 2025 |
| Countries | Australia, Belarus, Brazil, Bulgaria, Chile, China, Colombia, Czechia, Georgia, Greece, Hungary, Jordan and 12 more |
At a glance
- 100–999 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: